Back to results
US 2023/0056631 A1Published application
Tricyclic compounds as inhibitors of kras
AssigneeIncyte Corporation
InventorsPei Gan, Jeffrey Yang, Yong Li, Le Zhao, Chunhong He, Chunyin Marshall Law, Xiaozhao Wang, Wenqing Yao
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
Claims33
A compound having Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is N or OH;
- R1 is selected from Cl, CH3, CH2F, CHF2, and OF3;
- Cy1 is selected from
- R2 is selected from F and Cl;
- R3 is selected from
- and,
- Cy2 is selected from
- provided that the compound of Formula I is other than,
- 2-((2S,4S)-4-(7-(2-chloro-3-methylphenyl)-4-(3-(dimethylamino)-3-
- methylazetidin-1-yl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-
- 1-yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile,
- 2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-7-(2,3-
- dimethylphenyl)-6-fluoro-8-methyl-1H-[1,2,3]triazolo[4,5-c]quinolin-1-
- yl)-1-((E)-4-fluorobut-2-enoyl)piperidin-2-yl)acetonitrile, and
- 2-((2S,4S)-4-(4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(6-
- fluoro-5-methyl-1H-indazol-4-yl)-8-methyl-1H-[1,2,3]triazolo[4,5-
- c]quinolin-1-yl)-1-((E)-4-methoxybut-2-enoyl)piperidin-2-yl)acetonitrile.
15 more elements
Dependencies are inferred from the claim text.